HAL vs NBIX · P/E 9.3, $19.05B cap vs P/E 45, rev $2.36B
Halliburton Company (HAL) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
HAL does not have a complete income-statement cache yet.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
HAL currently screens at market cap $19.05B and trailing P/E 9.3. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the HAL and NBIX stock pages for the full models.
Not investment advice.